CRF Connect Logo
  • Tracks & Learning Series
    VIEW ALL
  • Conferences
  • My Favorites

Coronary

Techniques and Lesion Subsets Learning Series

Pharmacotherapy

Advertisement

Coronary >
Pharmacotherapy

Episodes

Where Do Antithrombotics Fit In?

Where Do Antithrombotics Fit In?

13 min.

Beyond LDL

Beyond LDL

14 min.

Expanding Your Lane and Not Your Waist: Cardiologists and GLP1-RA/SGLT2i

Expanding Your Lane and Not Your Waist: Cardiologists and GLP1-RA/SGLT2i

12 min.

Lipoprotein(a): Why Measure and What to Do?

Lipoprotein(a): Why Measure and What to Do?

11 min.

Applying New LDL-C Lowering Agents: Update on PCSK9mab, Inclisaran, and Bempedoic Acid

Applying New LDL-C Lowering Agents: Update on PCSK9mab, Inclisaran, and Bempedoic Acid

13 min.

Pharmacology for STEMI PCI: Which Therapies Before, Options During the Case, and Management Post

Pharmacology for STEMI PCI: Which Therapies Before, Options During the Case, and Management Post

13 min.

STEMI Pharmacotherapy: Oral and IV Antiplatelet Therapies, Intracoronary Lytic, Anticoagulants, and Early PCSK9 Inhibitors

STEMI Pharmacotherapy: Oral and IV Antiplatelet Therapies, Intracoronary Lytic, Anticoagulants, and Early PCSK9 Inhibitors

16 min.

Antithrombotic Therapy in ACS/PCI: Case Continuation and In Hospital Management

Antithrombotic Therapy in ACS/PCI: Case Continuation and In Hospital Management

4 min.

Unfractionated Heparin Still Works for Primary PCI!

Unfractionated Heparin Still Works for Primary PCI!

11 min.

Cangrelor Reduces Procedural Complications and Should Be the Default Strategy

Cangrelor Reduces Procedural Complications and Should Be the Default Strategy

9 min.

I Don’t Need Cangrelor With Available Potent Oral P2Y12 or 2b3a Inhibitors

I Don’t Need Cangrelor With Available Potent Oral P2Y12 or 2b3a Inhibitors

10 min.

Longer Term DAPT Is What The Guidelines and Data Support

Longer Term DAPT Is What The Guidelines and Data Support

7 min.

The Guidelines Need Updating: 3-6 Months of DAPT Is Sufficient

The Guidelines Need Updating: 3-6 Months of DAPT Is Sufficient

7 min.

Antithrombotic Therapy in ACS/PCI: Case Resolution and Long-term Therapy

Antithrombotic Therapy in ACS/PCI: Case Resolution and Long-term Therapy

8 min.

Bivalirudin Is the Most Evidence Based Antithrombin Agent for Primary PCI

Bivalirudin Is the Most Evidence Based Antithrombin Agent for Primary PCI

8 min.

Case Presentation: Antithrombotic Therapy in ACS/PCI

Case Presentation: Antithrombotic Therapy in ACS/PCI

3 min.

The Primary Endpoint Results from the COMPARE 60/80 HBR Trial: A Randomized Controlled Multi-Center Trial Comparing Ultrathin With Thin Strut Stents in High Bleeding Risk Patients With an Abbreviated DAPT Duration

The Primary Endpoint Results from the COMPARE 60/80 HBR Trial: A Randomized Controlled Multi-Center Trial Comparing Ultrathin With Thin Strut Stents in High Bleeding Risk Patients With an Abbreviated DAPT Duration

18 min.

Less Than 1-Month Dual Antiplatelet Therapy Followed by Ticagrelor Monotherapy After Coronary Drug-Eluting Stent Implantation for Acute Coronary Syndrome: A Randomized Trial

Less Than 1-Month Dual Antiplatelet Therapy Followed by Ticagrelor Monotherapy After Coronary Drug-Eluting Stent Implantation for Acute Coronary Syndrome: A Randomized Trial

18 min.

Antiplatelet Agents for Patients Undergoing PCI: Options and Pharmacologic Considerations

Antiplatelet Agents for Patients Undergoing PCI: Options and Pharmacologic Considerations

17 min.

Long Term Maintenance Antiplatelet Therapy After PCI

Long Term Maintenance Antiplatelet Therapy After PCI

15 min.

Dual Antiplatelet Therapy After PCI: Considerations for Duration and Choice Of Drug(s)

Dual Antiplatelet Therapy After PCI: Considerations for Duration and Choice Of Drug(s)

12 min.

De-Escalation of Antithrombotic Therapy: Why, in Whom, and How?

De-Escalation of Antithrombotic Therapy: Why, in Whom, and How?

19 min.

Standardizing the Language Around DAPT Post PCI: A Report From ARC With a Case Example

Standardizing the Language Around DAPT Post PCI: A Report From ARC With a Case Example

10 min.

How to Treat Microvascular Dysfunction

How to Treat Microvascular Dysfunction

14 min.

What’s Next in Antithrombotic Therapy?

What’s Next in Antithrombotic Therapy?

16 min.

Aspirin or Clopidogrel for Chronic Management?

Aspirin or Clopidogrel for Chronic Management?

12 min.

DAPT After PCI: Do We Need It at All?

DAPT After PCI: Do We Need It at All?

8 min.

DAPT Duration: Unsettled or Case Closed?

DAPT Duration: Unsettled or Case Closed?

13 min.

Guided Antiplatelet Therapy: Why, and in Whom?

Guided Antiplatelet Therapy: Why, and in Whom?

11 min.

Standardizing The Language Around DAPT: An ARC Initiative

Standardizing The Language Around DAPT: An ARC Initiative

12 min.

A Typical PCI Case in 2023 with Longitudinal Follow Up

A Typical PCI Case in 2023 with Longitudinal Follow Up

5 min.

For Most Patients, Only Spontaneous MI Is Relevant

For Most Patients, Only Spontaneous MI Is Relevant

6 min.

The Importance of Addressing Lipids in Patients With Complex PCI

The Importance of Addressing Lipids in Patients With Complex PCI

8 min.

Novel Approaches to Reduce and Reverse Bleeding in Complex PCI

Novel Approaches to Reduce and Reverse Bleeding in Complex PCI

8 min.

Periprocedural MI Matters to All Patients!

Periprocedural MI Matters to All Patients!

4 min.

Does It Matter What Stent I Use in a HBR Patient?

Does It Matter What Stent I Use in a HBR Patient?

8 min.

New and Emerging Pharmacology for ACS: Lipid Modulation and Anti-Inflammatory Agents

New and Emerging Pharmacology for ACS: Lipid Modulation and Anti-Inflammatory Agents

8 min.

New and Emerging Pharmacology for ACS: Factor XI Inhibition

New and Emerging Pharmacology for ACS: Factor XI Inhibition

6 min.

My Roadmap for Preprocedure and Intraprocedural Antithrombotic Therapy in Complex PCI

My Roadmap for Preprocedure and Intraprocedural Antithrombotic Therapy in Complex PCI

8 min.

PCI in Patients With AF: The Risk and Benefit of Antithrombotic Therapy

PCI in Patients With AF: The Risk and Benefit of Antithrombotic Therapy

7 min.

Short DAPT or De-Escalation After ACS

Short DAPT or De-Escalation After ACS

7 min.

P2Y12 Inhibitors in ACS: Which Agent in Which Patient and When?

P2Y12 Inhibitors in ACS: Which Agent in Which Patient and When?

7 min.

Does Bleeding Risk Outweigh Thrombotic Risk or Vice Versa?

Does Bleeding Risk Outweigh Thrombotic Risk or Vice Versa?

8 min.

This website uses cookies to ensure you get the best experience on our website. Read More